Annovis Bio announced its third quarter 2026 financial results and provided updates on its Phase 3 clinical trials for buntanetap, a drug targeting Alzheimer's and Parkinson's diseases. The DUET-AD Alzheimer's trial is fully enrolled with 862 patients, with the last patient visit scheduled for December 31, 2026, and topline data expected in March 2027. The company raised $21 million in a public offering to fund operations through this data readout. Annovis is also advancing open-label extension studies for both Alzheimer's and Parkinson's, aiming to evaluate long-term safety and efficacy of buntanetap. These milestones are critical as Annovis prepares for a New Drug Application filing based on the upcoming trial results.
Annovis Bio's recent corporate updates and Q3 2026 financial results come as Pluang's Health sector shows broad gains. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 19:41 WIB: out of 150 priced US health stocks, 99 rose and 43 fell. Notable movers include NVAX at USD 8.96 with a 1-day change of +2.28% and Pluang order activity of 1% Sell / 99% Buy, COO at USD 63.52 with a +2.14% change, and TVTX at USD 52.57 with a +1.96% change. Typical hold times on Pluang range from 9 to 60 days among these stocks.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
